LONDON, Jan. 20, 2016 /PRNewswire/ -- Are prescribing constraints costing your brand market share?
Doctors can't always prescribe the asthma/COPD drugs they want to prescribe. The reason: market barriers—things like pricing, reimbursement, guidelines, patient preferences, and more.
Barriers like these are a threat to leading brands' market share. But they also offer opportunities for brands to take market share from competitors.
FirstView's Market Access Impact in Asthma/COPD report takes an in-depth look at the way barriers affect asthma/COPD prescribing, and reveals which brands are winning and losing market share because of it. See what brands are included in this report
Not your market? Click here to see the US Edition
Answering key questions
Packed with physician insight into seven of the leading asthma/COPD brands, Market Access Impact in Asthma/COPD answers key questions like:
Seretide: a top brand in the US, where does Seretide rank in the EU5 market?
Eklira: would eliminating market barriers move Eklira ahead of competing brands?
Foradil: is reimbursement or patient preference the key to Foradil's market share gains?
Onbrez: which is the bigger problem for Onbrez: guidelines, or formulary availability?
Serevent: which competing brands does Serevent take the most market share from?
Spiriva: with nearly equal barrier-related gains and losses, what can Spiriva do to tip the scales in its favour?
Symbicort: where does over half of Symbicort's lost share go? (the answer may surprise you)
Key Issues Explored
Market Access Impact in Asthma/COPD explores key issues affecting asthma/COPD drug makers. You'll learn:
How barriers affect market access:
What brands do doctors prescribe the most?
How many prescriptions do barriers affect?
Which barriers have the biggest effect?
How barriers affect your brand:
How many doctors prescribe your brand? How many don't, but would consider it?
Why don't doctors prescribe your brand? What do they prescribe instead?
Which competing brands does your brand take market share from?
A Report Based on Expert Knowledge
Market Access Impact in Asthma/COPD is based on a survey of 150 EU5 physicians—78 pulmonologists and 72 general practitioners.
All respondents have:
Been practicing for 2+ years
Prescribed at least one of the listed products
Seen at least 50 patients with asthma or COPD in total in the last month
Get Answers On The Following Brands
Seretide (fluticasone/salmeterol; GlaxoSmithKline)
Eklira (aclidinium; AstraZeneca)
Foradil (formoterol Novartis/Merck & Co.)
Onbrez (indacaterol; Novartis)
Serevent (salmeterol; GlaxoSmithKline)
Spiriva (tiotropium; Boehringer Ingelheim)
Symbicort (budesonide/formoterol; AstraZeneca)
Add the US report to your order and get a free comparison report
Also available, the Market Access Impact in Asthma/COPD—US edition.
Based on a survey of 100 physicians from the United States, the report reveals how market barriers affect the leading asthma/COPD brands in the US market.
Order the EU5 and US reports together and you'll receive a free companion report comparing results from both markets.
Email us for details or call +1 212-220-0880 or +44(0)20.7665.9240
MONEY BACK GUARANTEE!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company's success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
Learn more at www.firstwordgroup.com.
Download the full report: https://www.reportbuyer.com/product/3362820/
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
For more information:
Research Advisor at Reportbuyer.com
Tel: +44 208 816 85 48